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We previously reported that the novel Pseudomonas aeruginosa toxin Cif is capable of decreasing apical membrane
expression of the cystic fibrosis transmembrane conductance regulator (CFTR). We further demonstrated that Cif
is capable of degrading the synthetic epoxide hydrolase (EH) substrate S-NEPC [(2S,3S)-trans-3-phenyl-2-oxi-
ranylmethyl 4-nitrophenol carbonate], suggesting that Cif may be reducing apical membrane expression of CFTR
via its EH activity. Here we report that Cif is capable of degrading the xenobiotic epoxide epibromohydrin (EBH)
to its vicinal diol 3-bromo-1,2-propanediol. We also demonstrate that this epoxide is a potent inducer of cif gene
expression. We show that the predicted TetR family transcriptional repressor encoded by the PA2931 gene, which
is immediately adjacent to and divergently transcribed from the cif-containing, three-gene operon, negatively
regulates cif gene expression by binding to the promoter region immediately upstream of the cif-containing operon.
Furthermore, this protein-DNA interaction is disrupted by the epoxide EBH in vitro, suggesting that the binding of
EBH by the PA2931 protein product drives the disassociation from its DNA-binding site. Given its role as a
repressor of cif gene expression, we have renamed PA2931 as CifR. Finally, we demonstrate that P. aeruginosa
strains isolated from cystic fibrosis patient sputum with increased cif gene expression are impaired for the
expression of the cifR gene.
Pseudomonas aeruginosa is a ubiquitous opportunistic patho-
gen known to infect a variety of organisms, including plants,
nematodes, fruit flies, and humans (19, 30, 49). Disease in
humans shows a relative lack of tropism, as infections caused
by P. aeruginosa can be found in tissues as varied as the skin,
ocular epithelia, and the lung (3, 28, 31). This pathogenic
plasticity is largely due to the presence of a multiplicity of
virulence factors which allow for colonization and the estab-
lishment of infection (1). This arsenal of virulence factors
includes the well-characterized type three secretion system and
its effector molecules, elastases, phospholipases, phenazines,
and rhamnolipids (6, 9, 25, 27, 44, 47, 52). These virulence
factors contribute to both acute and chronic infections associ-
ated with burn wounds, ocular infections, P. aeruginosa venti-
lator-associated pneumonia, and cystic fibrosis (CF).
The genetic disease CF is the result of heritable mutations
within the cystic fibrosis transmembrane conductance regulator
(CFTR), the most common of which is the deletion of the
phenylalanine at position 508 (18, 37, 38, 48). In healthy airway
epithelia cells, CFTR acts to directly regulate the flux of Cl
ions and, indirectly, the flux of Na ions and water across the
apical membrane (22, 37). Airway epithelial cells in CF pa-
tients demonstrate decreased functional CFTR at their apical
membrane; thus, there is altered Cl and Na ion and water
flux across this membrane, resulting in increased viscosity and
decreased height of the periciliary fluid, which in turn leads to
decreased ciliary beating and a subsequent loss of the muco-
ciliary elevator, a key component of the innate immune system.
This breach in mucociliary clearance allows for a number of
different pathogens, including P. aeruginosa, to colonize the CF
lung and establish chronic infections (5). Following initial col-
onization by environmental isolates, these bacteria undergo a
series of phenotypic changes including the acquisition of aux-
otrophy for various nutrients, alterations in quorum-sensing
machinery, and the overproduction of the exopolysaccharide
alginate (11–14, 41). The overproduction of alginate results in
the mucoid phenotype associated with P. aeruginosa sputum
isolates from chronically infected CF patients. The mucoid
phenotype has been well studied and is believed to be the
result of selective pressures including exposure to antibiotics as
well as the host innate immune system (12, 13, 35).
We previously described a novel P. aeruginosa toxin that is
packaged into outer membrane vesicles and is capable of
dramatically reducing apical membrane expression of CFTR
in several different epithelial cell lines (29, 46). This toxin,
known as Cif, was predicted to belong to the family of
epoxide hydrolases (EHs) and was experimentally shown to
degrade the synthetic EH substrate S-NEPC [(2S,3S)-trans-
3-phenyl-2-oxiranylmethyl 4-nitrophenol carbonate]. While
it is not entirely understood how this EH activity may reg-
ulate apical membrane expression of CFTR, epoxides and
their metabolites have been shown to act as signaling mol-
ecules in both endothelial and epithelial cells, regulating
processes as varied as vasodilation and Cl ion transport
(33, 42). We found that a subset of P. aeruginosa strains
isolated from the CF airway demonstrated a marked in-
crease in cif transcription relative to laboratory strains, sug-
gesting a role for Cif in the pathophysiology of CF.
Our previous demonstration that cif was differentially ex-
pressed in mucoid versus nonmucoid CF clinical isolates (29)
led us to investigate the regulation of cif gene expression. Here
we show that the Cif protein is capable of degrading the ep-
oxide epibromohydrin (EBH) and that this xenobiotic com-
pound induces cif gene expression via its ability to alter DNA
binding of the TetR family regulator CifR. Finally, we show
that reduced cifR gene expression can account for the high
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level of cif gene expression observed in the nonmucoid P.
aeruginosa CF sputum isolates.
MATERIALS AND METHODS
Bacterial strains, media, and chemicals. All of the bacterial strains and plas-
mids used in this study are shown in Table 1. All bacterial strains were grown in
lysogeny broth (LB) unless otherwise noted (2). Growth media were supple-
mented with antibiotics at the following concentrations: gentamicin, 10 g/ml
(Escherichia coli) and 100 g/ml (P. aeruginosa); and ampicillin, 150 g/ml (E.
coli) and 1.5 mg/ml (P. aeruginosa). All strains were grown at 37°C. Yeast cultures
were grown in either rich (yeast extract-peptone-dextrose) or minimal (SD-Ura;
Sunrise Science Products, San Diego, CA) media at 30°C. All restriction enzymes
were purchased from New England Biolabs (Beverly, MA). All plasmids were
constructed in E. coli Top10 cells using standard protocols or in Saccharomyces
cerevisiae INVSc1 (Invitrogen, Carlsbad, CA) using in vivo recombination and
electroporated or conjugated into P. aeruginosa strain PA14, as previously re-
ported (8, 40).
EBH degradation assays. EBH degradation by Cif was performed as previ-
ously described (7). Briefly, 50 g of purified Cif was incubated with EBH at a
final concentration of 10 mM in 20 mM HEPES buffer (pH 7.4) and 500 mM
NaCl for 30 min at 37°C. Sodium periodate in acetonitrile was added at final
concentrations of 1.67 mM and 30%, respectively, and incubated at room tem-
perature for 1 h. Epinephrine-HCl was then added to a final concentration of 1.5
mM. The reaction was allowed to continue for 15 min at room temperature prior
to removal of the supernatant and subsequent detection at a wavelength of 490
nM with a Molecular Devices SpectrMax M2 plate reader. Degradation of EBH
was demonstrated by a reduction in absorbance at 490 nM.
EBH induction assays. Wild-type P. aeruginosa PA14 was grown overnight in
LB at 37°C and subsequently diluted 1:100 in LB supplemented with EBH at the
concentrations indicated for each experiment. Cultures were grown at 37°C with
shaking to an optical density at 600 nm (OD600) of 1.0. Cultures (500 l) were
centrifuged and pellets were frozen at 80°C. Samples for protein analysis were
boiled in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) loading buffer as previously described and subsequently resolved using
SDS-PAGE. Cif protein expression was analyzed using standard Western blot-
TABLE 1. Strains, plasmids, and primers used
Strain, plasmid, or primer Relevant characteristic Reference or source
Strain
S. cerevisiae INVSc1 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 Invitrogen
E. coli Top10 F mcrA (mrr-hsdRMS-mcrBC) f80lacZM15 lacX74 recA1 ara139 (ara leu)7697 galU galK
rpsL (StrR) endA1 nupG
Invitrogen
SMC3505 E. coli Top10  pDPM73 (Cif-His) 29
SMC3814 E. coli Top10  pDPM79 (CifR-His) This study
P. aeruginosa PA14 Wild type
SMC1584 P. aeruginosa clinical isolate 29
SMC1586 P. aeruginosa clinical isolate 29
SMC1591 P. aeruginosa clinical isolate 29
SMC1593 P. aeruginosa clinical isolate 29
SMC3816 PA14 PA2931  pDPM79 This study
SMC3817 SMC1584  pMQ71 This study
SMC3818 SMC1584  pDPM79 This study
SMC3819 SMC1586  pMQ71 This study
SMC3820 SMC1586  pDPM79 This study
Plasmid
pMQ71 Arabinose-inducible expression vector Cbr Apr URA3 40
pMQ30 Allelic replacement vector; Gmr 40
pDPM79 PA2931 hexa-histidine fusion in pMQ71; Apr Cbr URA3 This study
pDPM84 PA2931 in-frame deletion plasmid; Gmr This study
Primer
PA2934_rt_1 5-CTCCTGGCCGGCATCGCCCTGACCTTCTCC-3
PA2934_rt_2 5-CCATTCGTACCAGGTCTGGCCGAAGCCGTGC-3
RplU_rt_1 5-GGTGGCAAGCAGCACAAAGTCACCG-3
RplU_rt_2 5-GCGGACCTTGTCGTGACGGCCGTGG-3
PA2931_rt_for 5-CCAGGGCTTCGCGGAACAGCCCTTCC-3
PA2931_rt_rev 5-GACACCGCCCTGCAGCGAGCCATGG-3
Cif_northern_for 5-BT-GCCGCGGCCTCCTGGCCGGCATCGCCC-3a
Cif_northern_rev 5-BT-CGGCGACCGTTCGCCGCTATAGCCGG-3
PA2931_ko_1 5-CGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACG GCTGGAAGGCTCCAAG
GTAGAATGGATGG-3
PA2931_ko_2 5-CAAGTAAATTTATAGTGATCGATACAAATATGAGCG GGTCGCATCAGGCCGCC-3
PA2931_ko_3 5-GGCGGCCTGATGCGACCCGCTCATATTTGTATC GATCACTATAAATTTACTTG-3
PA2931_ko_4 5-GTGAGCGGATAACAATTTCACACAGGAAACAGCTAT GACCGCAGGCGCTCGCGG
AAGCCTTGC-3
PA2931_His_for 5-GAAAATCTTCTCTCATCCGCCTCAATGATGATGATG ATGATGGGGCCAGGCGCGC
AGCGCCCGTTCG-3
PA2931_His_rev 5-CTCCATACCCGTTTTTTTGGGCTAGCCCAAGGA AGCACACATATGGCAACGCGAG
GCAGGCCAC-3
EMSA_5bt_for 5-BT-CCTGACCTCCATTATTTGTATCGATCAC-3
EMSA_5bt_rev 5-BT-GAGCAGGTTGGACATGGTCTTTTCC-3
EMSA_for 5-CCTGACCTCCATTATTTGTATCGATCAC-3
EMSA_rev 5-GAGCAGGTTGGACATGGTCTTTTCC-3
a BT, biotinylated.
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ting as previously described (29). RNA for semiquantitative reverse transcrip-
tion-PCR (sqRT-PCR) was harvested as described below.
Detection of the morB-PA2933-cif transcript. RNA for Northern blot analysis
was harvested as described below. Samples were prepared, electrophoresed, and
transferred as previously described(17). Briefly, 20 g of RNA was denatured
using formaldehyde and formamide in MOPS (morpholinepropanesulfonic acid)
buffer at 65°C for 15 min. Gel loading buffer was added to the denatured RNA,
which was subsequently electrophoresed in a MOPS-formaldehyde-agarose gel
for 1 h at 80 V. RNA was transferred to a Biodyne B modified nylon membrane
(Thermo Scientific, Rockford, IL) using a standard wicking transfer for 4 to 8 h.
Following cross-linking and blocking, 500 ng of a biotinylated cif-specific probe
was added to the blocking buffer and incubated at 65°C for 12 h. The cif probe
was synthesized using the biotinylated primers Cif_northern_for and Cif_north-
ern_rev (Table 1) in a standard PCR followed by gel purification. Membranes
were washed with SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and
SDS buffer and subsequently labeled with a steptavidin-horseradish peroxidase
conjugate followed by detection using a LightShift chemiluminescence kit per the
manufacturer’s instructions (Pierce, Rockford, IL).
Plasmid construction. Construction of the PA2931 deletion plasmid was per-
formed as previously described (40) using primers PA2931_ko_1, PA2931_ko_2,
PA2931_ko_3, and PA2931_ko_4. Amplicons were created using primer pair
ko_1 and ko_2 and primer pair ko_3 and ko_4 and were recombined using S.
cerevisiae INVSc1 (Invitrogen) into plasmid pMQ30 linearized with restriction
enzymes EcoRI, HindIII, and BamHI. The resulting recombinants were lysed
and plasmids recovered by using standard techniques. Plasmid pDPM84 was
transformed into wild-type P. aeruginosa strain PA14 as previously described (8),
and transformants were selected for on solid LB media supplemented with
gentamicin. Merodiploids were resolved on solid LB media supplemented with
10% sucrose as previously described (45).
Plasmid pDPM79 containing the C-terminal, six-histidine-tagged variant of
PA2931 was constructed using standard yeast recombination techniques. Briefly, the
PA2931 open reading frame (ORF) was amplified using primers PA2931_His_for
and PA2931_His_rev, which contain regions homologous to the PA2931 ORF and
the plasmid pMQ71. The resulting amplicon was recombined into the plasmid
pMQ71.
Purification of the Cif protein. Purification of the histidine-tagged Cif protein
was performed as previously described (29).
Purification of the CifR protein. The hexa-histidine-tagged variant of the
PA2931 protein was expressed from the arabinose-inducible pDPM79 plasmid in
E. coli Top10 cells (Invitrogen, Carlsbad, CA). Cells containing the plasmid were
grown overnight at 37°C in LB supplemented with ampicillin, diluted 1:100 in 1
liter of LB supplemented with ampicillin and 0.2% arabinose, and incubated with
shaking at 37°C for 8 h. Cultures were centrifuged at 7,000  g for 20 min. Cell
pellets were then mechanically lysed via French pressure lysis. Lysates were
centrifuged at 20,000 g for 30 min to remove cellular debris. Supernatants from
centrifuged lysates were fractionated utilizing an Amersham HisTrap FF 5-ml
nickel affinity column. Protein was eluted over a 20 to 500 mM imidazole
gradient, with the bulk of the purified PA2931 protein eluting at 100 mM.
Fractions containing PA2931 were pooled and concentrated using Amicon Ul-
tra-15 10-kDa centrifugation columns (Millipore, Billerica, MA). The protein
solution was then dialyzed against 20 mM Tris-500 mM NaCl, pH 7.5. The
protein concentration was determined by utilizing a Bio-Rad protein assay kit
(Bio-Rad, Hercules, CA). Protein purity was determined using SDS-PAGE
followed by staining with Coomassie blue.
EMSA. Electromobility shift assays (EMSA) were performed using a Light-
Shift chemiluminescence EMSA kit (Pierce, Rockford, IL) per the manufactur-
er’s instructions. The PA2931-morB intergenic region was amplified using prim-
ers EMSA_5bt_for, EMSA_5bt_rev, EMSA_for, and EMSA_rev, resulting in
either the biotinylated probe or the cold-competitor DNA. The biotinylated
probe was then incubated with the purified PA2931 protein for 30 min. Samples
were loaded onto 10 Tris-borate-EDTA–PAGE gels and electrophoresed. Fol-
lowing electrophoresis, samples were electro-transferred to a Biodyne nylon
membrane (Rockford, IL) in 0.5 Tris-borate-EDTA. Samples were then UV
cross-linked to the membrane and blocked according to the manufacturer’s
instructions. Labeling and subsequent detection were carried out using a strepta-
vidin-horseradish peroxidase conjugate and chemiluminescence, as described by
the manufacturer. When EBH was included in the EMSA experiments, it was
added simultaneously with the DNA probe and protein prior to incubation at
37°C.
RNA purification and cDNA synthesis. RNA purification and cDNA synthesis
were performed as previously described (29) with the following modifications:
strains for sqRT-PCR were grown overnight in LB medium and subsequently
diluted 1:100 in LB medium and grown to an OD600 of 1.0. Cultures (500 l)
were harvested and centrifuged at 16,000  g for 2 min, and the cell pellets were
frozen at 80°C. Strains were grown in triplicate, and two samples were har-
vested per replicate.
RESULTS
Cif degrades the epoxide EBH. We previously reported that
the P. aeruginosa secreted toxin Cif is capable of degrading the
generic EH substrate S-NEPC, suggesting that this protein
may act as an EH (29). A previous report by Jacobs et al.
identified a soil pseudomonad capable of surviving on and
degrading the xenobiotic epoxide EBH (24). Further analysis
demonstrated that the biochemical activity produced by this
pseudomonad was the result of a secreted protein with a mass
similar to that of the Cif protein. Functional analysis of the
secreted protein demonstrated that it was an EH. The amino
acid sequence of the N terminus of this EH and three CNBr-
generated fragments of the protein shared up to 40% identity
with the Cif protein. The work by Jacobs and colleagues, as
well as our previous demonstration that Cif could degrade
S-NEPC, led us to hypothesize that Cif may be capable of
degrading the xenobiotic epoxide EBH.
To assay EH activity with EBH as the substrate, we moni-
tored the production of the vicinal diol of EBH, 3-bromo-1,2-
propanediol. This product is readily oxidized by periodate,
producing aldehyde and ketone variants of 3-bromo-1,2-pro-
panediol. The oxidation of 3-bromo-1,2-propanediol by perio-
date results in the reduction of periodate. The reduction of
3-bromo-1,2-propanediol by periodate can be detected using
epinephrine, which itself is readily oxidized by periodate, re-
sulting in a red color. The reduction of periodate results in an
inability to oxidize epinephrine and hence no colorimetric
change (7). Thus, the degradation of EBH by Cif can be readily
assayed based on the fact that as more EBH is degraded, more
periodate is reduced, and hence less epinephrine is oxidized
(Fig. 1A).
When we incubated EBH with the buffer alone, we observed
a red color detected at OD490, indicating oxidation of the
epinephrine due to the presence of periodate (data not
shown). However, when purified Cif was incubated with EBH,
we observed an absorbance threefold less than what we ob-
served in the no-protein control, consistent with our hypothesis
that Cif is an EH and is capable of degrading EBH (Fig. 1B).
Furthermore, when Cif was heated to 95°C for 20 min (heat
kill), thus denaturing the protein, we saw a complete loss of the
EH activity compared to activity with the non-heat-treated
protein. As an additional control, supernatant from E. coli
Top10 cells harboring the empty vector pMQ70 was fraction-
ated using conditions similar to those used to purify the Cif
protein. Neither the supernatant alone nor fractions derived
from the supernatant of the empty vector strain demonstrated
any degradation of EBH (data not shown).
To further test Cif’s ability to degrade EBH, we performed
a dose-response experiment, incubating EBH with decreasing
amounts of purified Cif (Fig. 1C). Consistent with Cif’s ability
to degrade EBH, we observed decreasing EBH degradation
with decreasing concentrations of the Cif protein.
Both cif gene and Cif protein expression are induced by
EBH. The expression of a variety of catabolic genes is induced
in the presence of their cognate substrates. Typically, this in-
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creased gene expression is the result of a regulatory protein
that either induces gene expression or derepresses expression
in the presence of the cognate effector molecule. The obser-
vation that Cif is capable of degrading the epoxide EBH led us
to hypothesize that cif gene expression may be positively reg-
ulated in the presence of this molecule.
To assess the response of cif gene expression to EBH, we
grew wild-type P. aeruginosa PA14 in the presence of increas-
ing concentrations of EBH and then performed sqRT-PCR.
We found that the addition of EBH to P. aeruginosa cultures
resulted in a dose-dependent increase in cif transcript levels,
while the transcript levels of the control rplU transcript re-
mained largely unchanged (Fig. 2A).
To further confirm these results, wild-type P. aeruginosa
cultures grown under identical conditions were assayed by
Western blotting (Fig. 2B). We also found a dose-dependent
increase in Cif protein levels. These results demonstrate that
EBH is a potent inducer of cif gene expression, resulting in
increased Cif protein levels.
cif is transcribed as part of a three-gene operon. The obser-
vation that EBH induced expression of the cif gene led us to
further investigate the regulation of this gene. The chromo-
somal organization of the cif gene predicts that it belongs to a
three-gene operon with the morB and PA2933 genes (Fig. 3A).
To determine if in fact cif was transcribed as part of a polycis-
tronic mRNA, we performed Northern analysis using a biotin-
ylated probe specific for the cif gene. RNA was isolated from
wild-type PA14, the cif mutant, and the PA2931 mutant and
probed for cif gene expression.
A single band was detected at 4.2 kb, consistent with the
prediction that cif is cotranscribed with the morB and PA2933
genes (Fig. 3B). Due to relatively low cif transcription levels,
we were unable to detect the cif-containing operon transcript
via Northern analysis in the wild-type genetic background.
However, in a P. aeruginosa PA14 mutant that overexpresses
cif as a result of a mutation in the PA2931 ORF (see below),
we were able to detect the transcript of the appropriate size.
These data suggest that all three genes are transcribed from
the predicted promoter region immediately adjacent to the
morB gene.
PA2931 negatively regulates cif gene expression. With the
demonstration that cif gene expression was variable and induc-
ible, we next sought to identify genes that regulate cif gene
expression. Divergently transcribed from the morB gene is the
FIG. 1. Cif degrades the epoxide EBH. The degradation of epoxides by EHs creates highly reactive vicinal diols. The colorimetric detection of
these diols is outlined in panel A. Generation of the vicinal diol of EBH by Cif can be detected spectrophotometrically through the oxidation of
3-bromo-1,2-propanediol by periodate and subsequent analysis of the redox state of epinephrine added to the reaction. (B) Purified Cif (50 g)
was incubated with 10 mM EBH, and absorbance at 490 nm was monitored. Also shown is a heat-inactivated protein (heat kill) control. Data were
normalized to samples containing buffer alone. *, P value of0.05. Values are presented as specific activity (EBH degraded/min/mg Cif). (C) Dose
response of EBH degradation by Cif. Bar 1 shows 10 mM EBH and 50 g Cif; bar 2, EBH and 25 g Cif; bar 3, EBH and 12.5 g Cif; bar 4, EBH
and 6.25 g Cif; and bar 6, EBH and 3 g Cif. Samples were incubated at 37°C for 15 min. Values are presented as the OD490, with the OD490
measurements of each condition subtracted from the control condition containing EBH alone.
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PA2931 gene, predicted to encode a TetR family DNA-binding
protein. Members of this family are known to regulate gene
expression by binding to the promoter region and occluding
the RNA polymerase-binding site, thus inhibiting gene expres-
sion. Via in silico analysis, we found a predicted promoter
region immediately adjacent to the morB-PA2933-cif operon.
The relative proximity and orientation of the PA2931 gene led
us to hypothesize that it negatively regulates cif gene expres-
sion.
To test this hypothesis, a clean deletion of the PA2931 gene
was created in P. aeruginosa PA14. A hexa-histidine-tagged
variant of the cloned PA2931 gene was created in the multi-
copy, arabinose-inducible plasmid pMQ71 (40) (designated
pDPM79) to be used both in complementation studies here
and for expression of the PA2931 protein for purification de-
scribed below. RNA from these strains was isolated, and cif
and rplU gene expression were assayed by using sqRT-PCR.
These strains were also assayed for Cif protein expression by
using Western blotting.
Deletion of the PA2931 gene resulted in a marked increase
in cif gene expression (Fig. 3B and 4A). Introduction of the
PA2931 histidine-tagged variant expressed from the plasmid
pDPM79 into the PA2931 deletion strain resulted in a resto-
ration of wild-type levels of cif transcript.
The marked increase in expression seen in the PA2931
strain, compared to that in the wild-type strain, required the
use of a low number of PCR cycles in order to demonstrate the
difference in expression and to capture cif expression in
the PA2931 strain during the linear range of the PCR. These
PCR conditions resulted in almost undetectable levels of the
cif amplicon in the wild-type strain. The use of a higher number
of cycles on identical samples demonstrated that the cif tran-
script was detectable in the wild-type and complemented
strains but not in the cif mutant strain, as would be expected
(data not shown).
These data were further confirmed by using Western blot-
ting. Cif protein expression was increased in the PA2931 de-
letion strain carrying the empty vector pMQ71, while strains
expressing the histidine-tagged variant of the PA2931 protein
from the plasmid pDPM79 demonstrated reduced Cif protein
expression compared to that of the vector control (Fig. 4B).
These data taken together demonstrate that the protein
encoded by the PA2931 gene negatively regulates cif gene
transcription, resulting in decreased Cif protein expression.
Based on these data, we have renamed the PA2931 gene cifR,
reflecting its ability to repress cif gene expression.
CifR shows EBH-dependent binding upstream of the morB-
PA2933-cif operon. The TetR family of repressors has previ-
ously been shown to bind directly to the promoter region
upstream of the genes they regulate in the absence of their
cognate effector molecules (21, 23, 36). As mentioned above,
the CifR protein is predicted to be a TetR family member.
Considering this data together with the demonstration that the
cifR gene is important for repression of cif gene expression, we
hypothesized that CifR is repressing cif gene expression by
binding to the predicted promoter region directly upstream of
the morB-PA2933-cif operon (Fig. 5A). We employed EMSA
to study CifR-DNA interactions. If indeed CifR is capable of
binding to the cifR-morB intergenic region, a shift in migration
FIG. 2. EBH induction of cif gene and Cif protein expression. Wild-type (WT) P. aeruginosa strain PA14 was grown in LB supplemented with
increasing concentrations of the epoxide EBH. Expression of the cif gene and Cif protein in response to EBH was assayed using either sqRT-PCR
(A) or Western blotting (B), respectively. The expression of rplU, a gene previously shown to be constitutively expressed under most laboratory
conditions, served as a control (panel A). Samples for Western blotting were normalized to total protein content (panel B). The graphical
interpretation of the Western blot data shown in panel B is the relative Cif expression normalized to the total protein electrophoresed.
FIG. 3. cif is cotranscribed with morB and PA2933. (A) The cif
gene is predicted to belong to a three-gene operon including morB,
PA2933, and cif. (B) RNA from the wild type (WT) and the cif and
PA2931 mutants was assayed using Northern blotting to determine
the transcript size detected by the cif-specific probe. A single band at
4.2 kb was detected in the PA2931 mutant.
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of the probe should be observed when CifR is incubated with
the biotinylated probe.
The incubation of the purified CifR protein with the biotin-
ylated probe resulted in a substantial mobility shift consistent
with the formation of a CifR-DNA complex (lane 2, Fig. 5B,
lane 2), compared to the shift with probe alone (Fig. 5B, lane
1). This binding was shown to be sensitive to the addition of the
unlabeled cold probe, suggesting specificity of CifR for the
intergenic region (Fig. 5B, lane 3). As an additional control, we
utilized a nonspecific cold competitor derived from the rplU
gene from P. aeruginosa. Inclusion of the rplU amplicon at a
100 molar excess did not result in a decrease in CifR binding
to the biotinylated probe (data not shown).
The binding of CifR to the cifR-morB intergenic region is
concentration dependent; as CifR concentration increased, we
observed an increase in the CifR-DNA complex (Fig. 5C).
Interestingly, under the conditions assayed, binding was ob-
served at molar DNA-to-protein ratios as low as 1:100 (Fig. 5C,
lane 2). By using a best-fit curve to determine the half-maximal
effective concentration (EC50) of CifR binding to the inter-
genic region assayed, we found that CifR has an EC50 of
approximately 118 pM. As this system consists of only two
FIG. 4. cifR negatively regulates cif gene expression. cif gene and Cif protein expression were assayed using either sqRT-PCR or Western
blotting, respectively. (A) The wild type (WT), the cif mutant, and the PA2931 mutant harboring the empty vector pMQ71 or expressing the
PA2931 gene from the plasmid pDPM79 were assayed for cif and rplU gene expression. Deletion of the PA2931 gene resulted in higher levels of
cif gene transcript, which was complemented by expression of the histidine-tagged variant of PA2931. (B) Western blot of the WT P. aeruginosa
strain PA14, the PA2931 mutant containing the empty vector pMQ71, and the PA2931 mutant carrying a plasmid expressing a histidine-tagged
variant of PA2931 from the arabinose-inducible expression plasmid pDPM79. Arabinose was added to a final concentration of 0.2% where
indicated.
FIG. 5. CifR binds to the intergenic region directly upstream of the cif-containing operon. (A) The intergenic region between the cifR and morB
genes was amplified using biotinylated primers and used as a probe in EMSAs. (B) EMSA using the morB-cifR intergenic region as a probe and
purified CifR. Lane 1, labeled probe; lane 2, probe and 1.15 nM CifR; lane 3, probe, 1.15 nM CifR, and a 20 molar excess of the unlabeled cold
competitor; and lane 4, probe, 1.15 nM CifR, and 1 mM EBH. BT, biotinylated. (C) EMSA CifR dose response. Lane 1, probe alone; lane 2, probe
and 115 pM CifR; lane 3, probe and 287.5 pM CifR; lane 4, probe and 575 pM CifR; lane 5, probe and 862.5 pM CifR; and lane 6, probe and
1.15 nM CifR. (D) EMSA EBH dose response. Lane 1, probe alone; lane 2, probe and 1.15 nM CifR; lane 3, probe, 1.15 nM CifR, and 10 M
EBH; lane 4, probe, 1.15 nM CifR, and 100 M EBH; and lane 5, probe, 1.15 nM CifR, and 1 mM EBH.
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components, we can assume that it is noncompetitive, and thus
the EC50 value is approximately equal to the CifR/DNA bind-
ing constant.
Based on the finding that EBH stimulates cif gene expres-
sion in vivo, we tested whether EBH could impact the CifR-
DNA complex in vitro. The CifR-DNA complex is disrupted by
the addition of EBH (Fig. 5B, lane 4). This finding is in direct
agreement both with the results showing increased cif gene
transcription in the presence of EBH and with several reports
in the literature demonstrating that the presence and binding
of certain ligands to TetR family protein members results in
disassociation of the protein from its cognate DNA-binding
site (16, 26, 39). It should be noted that EBH does not gener-
ally disrupt DNA-protein complexes, as we have tested the
effects of EBH on another DNA-binding protein using EMSA
and found that there was no effect on binding (data not
shown).
As we showed in Fig. 2A and B, induction of cif gene expres-
sion and Cif protein expression by EBH is concentration depen-
dent between 10 M and 1 mM. As shown in Fig. 5D, the effect
of EBH on CifR DNA binding is also concentration dependent.
Interestingly, inhibition of the formation of the DNA-protein
complex occurs at concentrations similar to those observed for Cif
induction by EBH in vivo (Fig. 2A and B).
cif-overexpressing clinical isolates demonstrate altered cifR
gene expression. A previous report from our group demon-
strated that nonmucoid P. aeruginosa strains isolated from CF
sputum demonstrate relatively high levels of cif gene expres-
sion compared to levels associated with the lab strain P. aerugi-
nosa PA14 (29). We also found that mucoid CF isolates, those
producing high concentrations of the exopolysaccharide algi-
nate, had relatively lower levels of cif gene expression com-
pared to levels associated with PA14. The striking similarity
between the nonmucoid cif-overexpressing strains and the
cifR strain led us to hypothesize that the increased cif expres-
sion observed in these nonmucoid clinical strains was due to
decreased cifR gene expression.
Nonmucoid P. aeruginosa clinical isolates previously shown
to overexpress cif were assayed using sqRT-PCR for rplU, cif,
and cifR gene expression. All of the clinical isolates assayed
demonstrated increased cif expression compared to that of the
wild-type PA14 and compared to the rplU expression (Fig. 6A).
Interestingly, all of the nonmucoid clinical isolates also dem-
onstrated a marked decrease in cifR gene expression compared
to that with the wild-type laboratory strain PA14. Furthermore,
the one isolate that expressed slightly higher levels of cifR (lane
5) demonstrated a concomitant decrease in cif expression, sug-
gesting an inverse relationship between cif and cifR expression
in P. aeruginosa CF sputum isolates.
To further demonstrate that the cif overexpression pheno-
type was due to a decrease in cifR expression, the plasmid
pDPM79 expressing cifR was introduced into two of these
strains. We found that the expression of cifR in the nonmucoid
cif-overexpressing clinical strains results in a significant de-
crease in cif expression (Fig. 6B). Only two of four strains in
Fig. 6A were assayed, as isolation of stable transformants of
the other two strains was never achieved (data not shown).
The cif gene overexpression phenotypes appeared to be the
result of heritable changes in gene expression, as these pheno-
types were stable following serial passaging of the strains in
both solid and liquid media (data not shown). We hypothe-
sized that the loss of cifR expression in these clinical isolates
was due to changes within the promoter region of the cifR
gene. In order to identify any changes affecting cifR gene ex-
pression, we amplified the chromosomal region containing
both the cifR promoter region and the ORF and sequenced the
resulting amplicon. Surprisingly, there were no changes to the
promoter region. While there were changes within the cifR
ORF in these strains, none of these nucleotide changes were
predicted to result in either missense or nonsense mutations.
DISCUSSION
We have previously demonstrated that P. aeruginosa pro-
duces a novel toxin, Cif, which is capable of decreasing apical
membrane expression of CFTR in a variety of epithelial cell
culture lines (29, 46). In silico analysis of the predicted amino
acid sequence of this protein suggested that it may belong to
the large family of 	/
 hydrolases and in particular to the
family of EHs. Supporting this hypothesis, Cif was shown to
degrade the general model EH substrate S-NEPC.
The ability to degrade S-NEPC, while suggestive, was not
FIG. 6. Clinical isolates overexpressing the cif gene demonstrate decreased cifR gene expression. (A) sqRT-PCR of wild-type P. aeruginosa
PA14 and four nonmucoid P. aeruginosa CF sputum isolates. Expression of the cif, cifR, and rplU genes was assayed. (B) sqRT-PCR of wild-type
(WT) P. aeruginosa, the cif and cifR mutants, and two of the clinical isolates from panel A carrying either the empty vector pMQ71 () or the
cifR-expressing plasmid pDPM79 ().
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conclusive evidence that Cif is an EH. In order to better un-
derstand the biological activity of Cif, i.e., decreased apical
membrane expression of CFTR, we sought to further charac-
terize the biochemical activity of this protein. Previous work
identified a soil pseudomonad capable of degrading the ep-
oxide EBH (24). This previous study demonstrated that this
EH activity was the result of a secreted protein with a mass and
amino acid sequence similar to those to the Cif protein, leading
us to hypothesize that Cif may be a homolog of the EH de-
scribed previously that would thus be capable of degrading
EBH. The finding that Cif could indeed degrade EBH sup-
ported this hypothesis. Furthermore, the demonstration that
EBH could significantly induce cif gene expression supports
the conclusion that this family of molecules can serve as sub-
strates for Cif.
Epoxides have been previously shown to act as signaling
molecules regulating processes as varied as Cl ion transport
in renal tubular epithelial cells, angiogenesis, and vasodilation
mediated by endothelial cells (32, 33, 42). Furthermore, sev-
eral studies have demonstrated the presence of high levels of
leukotrienes within the CF airway. Leukotrienes are produced
from the inactive epoxide molecule leukotriene A4, which is
metabolized by the EH leukotriene hydrolase to the active,
vicinal diol form, leukotriene B4. Leukotriene B4 has been
shown to be a potent chemoattractant, specifically for neutro-
phils, and is generally considered a mediator of inflammation
(10, 32, 34, 50, 51). It still remains unclear how Cif alters apical
membrane expression of CFTR, but it may be through the
metabolism of these epoxide signaling molecules. Thus, CifR
may regulate cif gene expression, and hence Cif biosynthesis,
by binding of native epoxide molecules in the CF lung. These
molecules have yet to be identified. While we do not believe
that EBH, an industrial pollutant, is found in the CF lung, or
acts as a signaling molecule within the CF lung, it serves as a
model compound for better understanding the regulation of cif
gene expression by CifR.
The family of TetR repressors has been shown to regulate
the expression of genes involved in a variety of pathways, from
antibiotic resistance to carbon catabolism (20, 23, 36). Typi-
cally TetR family members have a DNA-binding helix-turn-
helix (HTH) motif as well as an effector-binding domain. The
protein acts to regulate gene expression by binding to the
promoter region of its target gene and thus inhibiting tran-
scription. The presence of an effector causes conformational
shifts in the HTH domain, resulting in disassociation of the
protein from the promoter and hence derepression of gene
expression (16, 21, 26, 36). Comparison of the CifR amino acid
sequence to known TetR family members showed a similar
organization, including a HTH DNA-binding domain and a
predicted effector-binding domain with no homology to any
known TetR protein. We have shown here that the CifR pro-
tein is capable of binding to the predicted promoter region of
the cif-containing operon and that this interaction is sensitive
to the epoxide EBH (Fig. 7). These data readily explain the
EBH-dependent induction in cif gene expression shown in Fig.
2A. Interestingly, we found that this disassociation was con-
centration dependent and that this phenomenon occurred at
concentrations similar to those shown in Fig. 2A, indicating
that the concentration of EBH used to disrupt the DNA-
protein complex in the in vitro studies is physiologically rele-
vant.
In silico analysis of the cifR-morB intergenic region has iden-
tified a putative CifR-binding site consisting of two palin-
dromic sequences that overlap both the putative 10 and 35
sequences of the morB and cifR promoters. Work is ongoing to
identify and characterize the CifR-binding site. Interestingly,
the putative promoter regions of the morB and cifR genes
overlap significantly, as does the putative CifR-binding site.
Thus, most likely, CifR not only represses expression of the
cif-containing operon but also negatively regulates its own ex-
pression in the absence of EBH.
We have previously demonstrated that nonmucoid P. aerugi-
nosa strains isolated from CF sputum demonstrated signifi-
cantly increased cif gene expression compared to that with the
P. aeruginosa strain PA14 (29), while mucoid CF isolates dis-
played lower levels of cif gene expression. These observations
led us to hypothesize that the differential cif gene expression
was the result of changes in expression of CifR. In support of
this hypothesis, we found that in several of the nonmucoid
strains overexpressing cif, cifR gene expression was signifi-
cantly lower than the expression seen in the laboratory strain
PA14. Furthermore, when CifR was expressed from the plas-
mid pDPM79 in two of the cif-overexpressing clinical isolates,
we observed a level of cif transcript that was significantly lower
than that with the vector control strains. Interestingly, the cif
overexpression phenotype of nonmucoid clinical isolates was
FIG. 7. Model for cif gene expression. CifR represses cif gene expression by binding to the promoter region immediately adjacent to the
cif-containing operon. The binding of EBH by CifR results in disassociation of the repressor from the promoter, resulting in increased cif gene
expression and biosynthesis of the EH Cif, which in turn degrades EBH.
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stable, as repeated passaging of the strains in laboratory media
did not effect cif gene expression, suggesting that these strains
had acquired mutations either in the cifR promoter region or
within the ORF itself. However, DNA sequence analysis of the
cifR promoter region did not illuminate any mutations in the
promoter. We did find several mutations within the ORF,
although none of these are predicted to result in either mis-
sense or nonsense mutations. Several models for the decreased
expression of cifR in these strains can be invoked, including
changes in mRNA stability, structural changes in the mRNA,
or changes in genes that regulate cifR expression. Currently, we
believe the latter to be the case, and studies are ongoing to
identify regulators of both cif and cifR gene expression.
It is generally believed that CF patients are initially colo-
nized by nonmucoid environmental isolates, which eventually
convert to the mucoid phenotype (4, 15, 35, 43). These data,
taken together with our demonstration that nonmucoid clinical
isolates show relatively high cif expression compared to that of
mucoid clinical isolates, suggest that Cif may play a role in
initial colonization of the CF lung and early infection. Classi-
cally, TetR family regulators have been shown to regulate gene
expression as a response to environmental stimuli, as is the
case with CifR and its response to EBH. We hypothesize that
CifR may respond to the presence of an endogenous epoxide
and regulate cif gene expression accordingly, thus affecting
CFTR membrane expression through an as-yet-unidentified
mechanism.
An alternative hypothesis is that there is a selective pressure
for strains that overexpress cif in the context of the CF lung
and that this pressure leads to a population that has increased
cif expression as a result of decreases in cifR expression. The
demonstration that the cif-overexpressing phenotype in clinical
isolates was heritable and stable in these strains suggests that
this phenotype is due to genotypic changes altering cifR gene
expression. Thus, rather than sensing the environment and
responding through classic regulatory pathways, it would ap-
pear that P. aeruginosa in the CF lung may simply remove the
regulatory elements for some genes, thus altering their basal
gene expression.
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